Ceglarek U, Schellong P, Rosolowski M, et al. - Because excessively high death rates due to cardiogenic shock (CS) complicating acute myocardial infarction (AMI) are still reported, therefore, researchers sought to construct a new readily applicable biomarker-based risk score. This score for 30-day mortality was built using 458 patients with CS complicating AMI involved in the randomized CULPRIT-SHOCK trial. For validation, 163 patients with CS incorporated in the randomized IABP-SHOCK II trial were used. There were 58 candidate variables, of those, the four strongest predictors (cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide) for 30-day death were incorporated in the CLIP score. Herein, the development, extensive validation as well as calibration of a biomarker-only score for 30-day mortality risk stratification in infarct-related CS was accomplished using a prospective cohort of contemporary patients with CS post-AMI. The performance of the CLIP score was better than that of the other clinical scores, and CLIP score may afford a beneficial early decision tool in CS.